Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

Xiaoyang Wang; Robert Lopez; Rebecca Luchtel; Sassan Hafizi; Benjamin Gartrell; Niraj K. Shenoy

doi:10.1016/j.kint.2020.08.028

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

Xiaoyang Wang, Robert Lopez, Rebecca Luchtel, Sassan Hafizi, Benjamin Gartrell, Niraj K. Shenoy^*

^*Corresponding author for this work

Albert Einstein College of Medicine

Research output: Contribution to journal › Literature review › peer-review

116 Downloads (Pure)

Abstract

Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. A comprehensive understanding of the mechanisms of immune evasion in RCC is therefore critical to the development of effective combination treatment strategies. This article reviews the current understanding of the different, yet coordinated, mechanisms adopted by RCC cells to evade immune killing; summarizes various aspects of clinical translation thus far, including the currently registered RCC clinical trials exploring agents in combination with checkpoint inhibitors; and provides perspectives on the current landscape and future directions for the field.

Original language	English
Pages (from-to)	75-85
Number of pages	11
Journal	Kidney International
Volume	99
Issue number	1
Early online date	16 Sept 2020
DOIs	https://doi.org/10.1016/j.kint.2020.08.028
Publication status	Published - 1 Jan 2021

Keywords

biology
carcinoma, renal cell/drug therapy
forecasting
humans
immune evasion
immunotherapy
kidney neoplasms/drug therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2020.08.028

Wang_et_al_AAM_2020Accepted author manuscript (Post-print), 707 KBLicence: CC BY-NC-ND

Cite this

@article{a5d1650f3bf54929be63185564611e29,

title = "Immune evasion in renal cell carcinoma: biology, clinical translation, future directions",

abstract = "Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. A comprehensive understanding of the mechanisms of immune evasion in RCC is therefore critical to the development of effective combination treatment strategies. This article reviews the current understanding of the different, yet coordinated, mechanisms adopted by RCC cells to evade immune killing; summarizes various aspects of clinical translation thus far, including the currently registered RCC clinical trials exploring agents in combination with checkpoint inhibitors; and provides perspectives on the current landscape and future directions for the field.",

keywords = "biology, carcinoma, renal cell/drug therapy, forecasting, humans, immune evasion, immunotherapy, kidney neoplasms/drug therapy",

author = "Xiaoyang Wang and Robert Lopez and Rebecca Luchtel and Sassan Hafizi and Benjamin Gartrell and Shenoy, {Niraj K.}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/j.kint.2020.08.028",

language = "English",

volume = "99",

pages = "75--85",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

AU - Wang, Xiaoyang

AU - Lopez, Robert

AU - Luchtel, Rebecca

AU - Hafizi, Sassan

AU - Gartrell, Benjamin

AU - Shenoy, Niraj K.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. A comprehensive understanding of the mechanisms of immune evasion in RCC is therefore critical to the development of effective combination treatment strategies. This article reviews the current understanding of the different, yet coordinated, mechanisms adopted by RCC cells to evade immune killing; summarizes various aspects of clinical translation thus far, including the currently registered RCC clinical trials exploring agents in combination with checkpoint inhibitors; and provides perspectives on the current landscape and future directions for the field.

AB - Targeted therapies and immune checkpoint inhibitors have advanced the treatment landscape of Renal Cell Carcinoma (RCC) over the last decade. While checkpoint inhibitors have demonstrated survival benefit and are currently approved in the front-line and second-line settings, primary and secondary resistance is common. A comprehensive understanding of the mechanisms of immune evasion in RCC is therefore critical to the development of effective combination treatment strategies. This article reviews the current understanding of the different, yet coordinated, mechanisms adopted by RCC cells to evade immune killing; summarizes various aspects of clinical translation thus far, including the currently registered RCC clinical trials exploring agents in combination with checkpoint inhibitors; and provides perspectives on the current landscape and future directions for the field.

KW - biology

KW - carcinoma, renal cell/drug therapy

KW - forecasting

KW - humans

KW - immune evasion

KW - immunotherapy

KW - kidney neoplasms/drug therapy

U2 - 10.1016/j.kint.2020.08.028

DO - 10.1016/j.kint.2020.08.028

M3 - Literature review

SN - 0085-2538

VL - 99

SP - 75

EP - 85

JO - Kidney International

JF - Kidney International

IS - 1

ER -

Immune evasion in renal cell carcinoma: biology, clinical translation, future directions

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this